Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18918512 | 1.00 | CHRM3 (0.37) | CHRM3CHRM2CHRM1ADRB2CHRM4 | |
| SCHEMBL18943231 | 0.83 | EPHX1 (0.39) | EPHX2 | |
| SCHEMBL23223983 | 0.79 | EPHX1 (0.38) | EPHX2 | |
| SCHEMBL18918491 | 0.76 | ADRB2 (0.66) | CHRM3ADRB2 | |
| SCHEMBL23198076 | 0.76 | ADRB2 (0.66) | CHRM3ADRB2 | |
| SCHEMBL18918487 | 0.76 | ADRB2 (0.66) | CHRM3ADRB2 | |
| SCHEMBL18918509 | 0.73 | CHRM3 (0.54) | CHRM3CHRM2CHRM1ADRB2CYP2D6 | |
| SCHEMBL18918507 | 0.73 | CHRM3 (0.54) | CHRM3CHRM2CHRM1ADRB2CYP2D6 | |
| SCHEMBL20477684 | 0.69 | CHRM3 (0.48) | CHRM3CHRM2CHRM1ADRB2CHRM4 | |
| SCHEMBL23198105 | 0.67 | ADRB2 (0.81) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383867-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2021-04-14 | — | — | EP | disclosed |
| EP-3383867-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2018-10-10 | — | — | EP | disclosed |
| US-9932338-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093208-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 10/4885CHRM2 8/4885CHRM1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.